This inventor holds 69 USPTO granted patents and 22 published patent applications, plus 1 CIPO patent and 22 EPO patents, primarily in Pharmaceutical Inhibitors (CPC class C07D). Top assignees: Takeda Pharmaceutical Company Limited, Jiangsu Hengrui Medicine Company Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.. Active years: 2009-2026.
Inventors with similar research interests:
Location History:
- Jiangsu, CN (2013 - 2016)
- Morris Plains, NJ (US) (2020)
- Shanghai, CN (2013 - 2021)
- San Diego, CA (US) (2009 - 2024)
- San Francisco, CA (US) (2023 - 2024)
Company Filing History:
20 out of 1,222 
15 out of 159 
15 out of 100 
Years Active: 2009-2026
Areas of Expertise:
Title: The Innovative Mind of Qing Dong: Pioneering Therapeutic Solutions
Introduction
Qing Dong, based in San Diego, California, is a prolific inventor with an impressive portfolio of 58 patents. His work primarily focuses on the pharmaceutical field, addressing critical health issues through innovative drug development. His inventions are instrumental in paving the way for new treatments in various medical conditions.
Latest Patents
Among his latest contributions to the field are notable inventions such as "Pyridinone MK2 inhibitors and uses thereof." This patent describes MK2 inhibitors and pharmaceutical compositions that are useful for treating autoimmune, chronic, acute, auto-inflammatory, fibrotic, metabolic, neoplastic, and cardiovascular disorders. Another significant patent is for "Substituted pyridines as PARP1 inhibitors," detailing tricyclic PARP1 inhibitors that provide potential cancer treatments.
Career Highlights
Throughout his career, Qing Dong has made substantial contributions while working with esteemed companies such as Takeda Pharmaceutical Company Limited and Jiangsu Hengrui Medicine Company Ltd. His expertise in drug development has established him as a key figure in advancing pharmaceutical research.
Collaborations
Qing Dong’s innovative journey has been complemented by his collaborations with respected colleagues, including Stephen W Kaldor and Piaoyang Sun. These partnerships have fostered a productive environment for scientific exploration and the sharing of knowledge, further enhancing the impact of their collective work.
Conclusion
Qing Dong's dedication to innovation in the pharmaceutical sector has led to the development of groundbreaking therapeutic solutions. With a remarkable collection of patents, his work continues to influence the treatment landscape for various diseases, showcasing the importance of innovation in advancing healthcare.